// App-Quantinova.ai

: TROPHU-U-01 cohort 5: Evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC).

Researchers

Presenter

  • Thomas Powles

Principal Investigators

  • Andrea Necchi

  • Ignacio Duran

  • Yohann Loriot

  • Chethan Ramamurthy

  • Alejandro Recio-Boiles

  • Randy F. Sweis

  • Jens Bedke

  • Julia Tonelli

  • Mitch Sierecki

  • Petros Grivas

  • Philippe Barthelemy

Medical Centers

  • University of Arizona Cancer Center, Tucson, AZ

  • Institut de Cancérologie Strasbourg Europe,Strasbourg, France, Strasbourg, France

  • Institut de Cancérologie Gustave Roussy, Université Paris-Saclay, Villejuif, France

  • Barts Cancer Institute & St.Bartholomew's Hospital, London, United Kingdom

  • University of Washington, WA

  • University of Tuebingen, Tuebingen, Baden Wurttemberg, Germany

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • IRCCS Ospedale San Raffaele, Milan, Italy

  • Gilead Sciences, Inc, Morris Plains, NJ

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • The University of Chicago Medical Center, Chicago, IL

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

Locations

  • Germany

  • Italy

  • France

  • Spain

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Creatinine

Drug/Treatment

  • IMMU132

  • Cisplatin

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Cohort

Phase

  • II

Study Id's

  • NCT03547973

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved